Cannabis Science, Inc. Announces New Company Website, New Management Team Expansions, & Pushes to Complete Updated Financial Reporting Requirements

Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce it is in the final process of releasing its new corporate website. The Company as well is about to announce some exciting new key management changes and expansions. While the Company deals with its exponential growth, key acquisitions, multiple dispensary openings, new important research opportunities, exciting new partnerships, and the required operation expansions, it is pushing to complete updating its financial reporting requirements.

“Our new website has been revamped and just about ready to launch. It will certainly exemplify our current outstanding growth cycle, our current business model, and fundamental corporate culture changes over the past few years. I think everyone will enjoy the new site; it’s certainly user-friendly, as they say, ‘a picture is worth a thousand words’, there are plenty of images and we have so many more to add. We are focusing on becoming more interactive and data-oriented in order to provide our patients, doctors, shareholders and interested parties better access to useful information and live real-time communications.  For example, through our successful Beta launch of iCannabinoid and a better view of Cannabis Science through new video releases, TV Commercials, www.cannabisscience.com, public service announcements, documentaries, magazines, and TV shows, our goals, our patients and their successes, our successes, and our achievements, and certainly most important; what’s planned for the future.

“We’ve had quite a multitude of tremulous experiences this last year, we’ve lost some key people whose names are written down in History already for their Achievements and Accolades. We have been going down this path of Greatness with the thorns along the way, we will continue down this path stronger and faster, with bigger clippers. We have equally had some of the most historical success stories on the planet. It’s certainly time for the Company to proceed to the next level. We are already at such a high level on so many capacities that this type of success will only you push to expand your key management team and bring on those to help take you to the next levels and beyond. So, we have done just that, we have added some key people to march, direct, and consult with us on this path of healing, history, and greatness. The Company will announce these changes and additions over the coming few days.

“Our financial team is working hard with our auditors to bring our filings up-to-date.  Our legal team is working in conjunction on reporting our current legal status on our cases for its reporting compliance. With all the new exciting successes and operational activity, the company has expanded dramatically.

“With several key acquisitions, the dispensaries openings and operations required, undue lawsuits, permitting and license applications, the day to day legal and accounting work getting done by our team is all very impressive, however, there is no way that they can handle the workload and we have decided to add to our legal department to ease this burden.

“We are raising capital to expand our operations team dramatically in almost every area; I guess this is when they say we have a ‘Happy Problem’. We expect to begin filing updated financials shortly, working through each reporting period step by step. Once completed I’m very confident our new procedures and operation expansions will take over the engine and get things back to normal with a much higher capacity to handle our grow and instant operational expansion requirements,” stated Mr. Raymond C. Dabney, Cannabis Science’s President & CEO, and Co-Founder.

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.